HL-1186
Phase 2Small molecule
HL-1186 is one of 54 small molecule programs targeting Neuropathic Pain. It is currently in Phase 2.
2
Indications
5
Total Trials
5
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
212 competitors in Neuropathic Pain
#DrugCompanyPhaseTrials
1Elavil
AstraZenecaPhase 3
Namenda
AbbViePhase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Briviact
UCBPhase 3
Sativex
Jazz PharmaceuticalsPhase 3
Ketalar
Boehringer IngelheimPhase 3
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ultram
WWim Janssens
Phase 3
Paxil
SSebela Pharmaceuticals Development LLC
Phase 3
Marcaine
IInnocoll
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postoperative Pain Management1 trial
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07311369·40 enrolled
Tics1 trial
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 1·NCT06912295·76 enrolled
Safety and Efficacy1 trial
Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07147049·72 enrolled
Neuropathic Pain1 trial
Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
Not yet recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07159243·180 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HL-1186. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details